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Catheter Ablation of Atrial Fibrillation,
Have All of Our Wishes Been Granted?
A Perspective on the SMART-AF Trial*Hugh Calkins, MDD uring the 16 years that have passed sinceﬁrst identiﬁcation of the pulmonary veins(PVs) as a common site for focal triggers
that initiate atrial ﬁbrillation (AF), catheter ablation
of AF hasmatured as a treatmentmodality. AF ablation
is now recommended as a Class 1 therapy for treatment
of patients with symptomatic AF refractory to at least 1
membrane active antiarrhythmic medication (1–3).
Despite the well-established safety and efﬁcacy of AF
ablation, its outcomes remain imperfect, falling far
below outcomes achieved with ablation of other less
complex arrhythmias. It is well recognized that
“re-do” procedures are far from rare, and are required
in up to 50% of patients (4,5). When a repeat AF abla-
tion procedure is performed, reconnection of 1 or
more PVs is present in nearly 100% of patients (6,7).
A good ﬁrst step to improving the single procedure
efﬁcacy of AF ablation would be to create more perma-
nent ablation lesions that translate into more perma-
nent PV isolation. In addition to power and time,
which are the conventional parameters adjusted dur-
ing radiofrequency (RF) ablation, contact force (CF) is
a third and critically important variable (8). Despite
the long-recognized importance of electrode-tissue
contact, only recently were ablation catheters devel-
oped that had the capability to measure CF (9,10).SEE PAGE 647In this issue of the Journal, Natale et al. (11) report
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efﬁcacy of a novel RF ablation catheter capable of
CF sensing. The investigational catheter was inserted
into 161 patients, and RF energy was delivered to
160. Among these patients, 38 patients were in the
“roll-in” cohort and used for the safety analysis only
and the remaining 122 patients comprised the effec-
tiveness cohort. Each patient had paroxysmal AF with
at least 3 symptomatic AF episodes (1 documented)
within the 6 months before enrollment. Each patient
had failed at least 1 Class 1 or 3 antiarrhythmic agent
or an AV nodal blocking drug. Five of these 122 pa-
tients were lost to follow-up. These patients were
seen in clinic at 1, 3, 6, 9, and 12 months post-ablation
with a 3-month blanking period. By Kaplan-Meier
analysis, the 12-month success rate was 72.5%. The
average CF was 17.9  9.4 g. When the CF employed
was between the investigator-selected ranges (>80%
of the time during ablation), efﬁcacy increased by
15% compared to cases where the time in optimal
range was less than this. The average procedure time
was 3.7  1.4 h, the average ablation time from ﬁrst to
last ablation was 2.0  1.0 h, and the average ﬂuoros-
copy time was 41.5 26 min. PV isolation was required
during all ablation procedures. More extensive abla-
tion procedures targeting lines, focal targets, and/or
nonfocal targets were performed in 50%. Among the
entire 161 patients included in the safety cohort, 4 pa-
tients had cardiac tamponade (2.5%) and 4 had vas-
cular complications, 2ofwhich requiredsurgical repair.
This study, which evaluated the safety and efﬁcacy
of AF ablation using an irrigated force-sensing abla-
tion catheter, is a welcome addition to the literature. I
commend the authors for their efforts to complete
this clinical. In an attempt to put the results into
context, there are several questions to address. First,
what are the strengths, limitations, and unique
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ered when interpreting the results? Second, what
information does this trial provide concerning the
importance of force monitoring during AF ablation?
Finally, what impact, if any, will CF-sensing catheters
have on the outcomes of AF ablation?
Considering the trial’s design, the strengths include
the fact that thiswas a prospective,multicenter clinical
study performed under the Food and Drug Adminis-
tration’s watchful eye, as part of an approval process.
Study entry criteria and endpoints were carefully
deﬁned and post-ablation monitoring was quite
robust. The weaknesses of this trial also are worth
considering, and the number of patients enrolled in the
efﬁcacy arm was relatively small (n ¼ 122); with the
success deﬁned as freedom from symptomatic AF/
atrial tachycardia/atrial ﬂutter >30 s on or off a
previously failed antiarrhythmic medication after #3
ablation procedures performed within 3 months of
the initial ablation procedure. When the stricter deﬁ-
nition of success recommended by the Heart Rhythm
Society Consensus Document (1) (single procedure, off
drug, 12-month follow-up, symptomatic or asympto-
matic) is employed, the ablation efﬁcacy falls to 66%,
more than 50% of ablation procedures were performed
with a deﬂectable sheath which both enhances cath-
eter stability, the risk of perforation, and cost, and 50%
of all patients underwent more extensive ablation
lesion sets than circumferential PV isolation alone.
Interestingly, no difference in outcomes was observed
for those patients who underwent PVI alone versus
those who had more extensive ablation. It is also
notable that the mean procedure duration was 3.7 
1.4 h with 2 h of RF ablation time and 41.1  26 min of
ﬂuoroscopy time per patient. It is clear that the oper-
ators were committed to a successful outcome of the
trial and did not expedite the ablation procedure.
If the goal of this trial was to test the hypoth-
esis that monitoring CF matters, and that this new
ablation catheter is superior to the prior generation
of irrigated RF ablation catheter, I would conclude
that this trial was a bust. A prospective, randomized
trial would have been required. Unfortunately, the
opportunity to perform a randomized trial of this
catheter was missed and may never be performed.
Fortunately, the results of a prospective randomized
clinical trial, which randomized AF patients to abla-
tion with a standard irrigated RF ablation catheter or
to another CF-sensing irrigated RF ablation catheter
(Endosense TactiCath, St. Jude Medical, St. Paul,
Minnesota), should be available soon. The goal of
the present trial was to receive Food and Drug Ad-
ministration approval of the SmartTouch catheter
(Biosense Webster, Inc., Diamond Bar, California) forcommercial use. When interpreted in this light, this
trial was a success, as sufﬁcient evidence was obtained
to demonstrate the safety and efﬁcacy of this ablation
catheter. This force-sensing ablation catheter is now
available for clinical use in the United States.
However, what do the results of this trial tell us
about the role of CF monitoring during AF ablation?
One critical perspective could accurately suggest “not
much.” Although the efﬁcacy of the force-sensing
ablation system was superior to that reported in the
original ThermoCool AF trial (72.5% vs. 66.0%), this
may or may not be the result of CF monitoring (12).
The ablation ﬁeld has advanced considerably since
2004 when this prior trial was launched. We now
have a better appreciation for the importance of
permanent PV isolation. We now know that the use
of deﬂectable sheaths improves outcomes. We now
have the beneﬁt of nearly a decade of additional
experience performing AF ablation. So, is the 10%
improvement in efﬁcacy due to force monitoring?
Firm conclusions are challenging, despite the post
hoc analysis that revealed that operators who ob-
tained the best results kept CF in their ideal range at
least 80% of the time. Based on this, I would antici-
pate that cardiac tamponade would be avoided by
knowing the CF. But this was not the case. In fact,
2.5% of ablation procedures resulted in tamponade.
This is far higher than the 1% reported incidence of a
pericardial effusion in the original ThermoCool trial
(12). This may reﬂect the use of a deﬂectable sheath
in more than 50% of procedures.
In conclusion, it is clear that ablation catheters
that allow CF monitoring will become the new stan-
dard for RF ablation. The value of CF monitoring is
immediately clear when using these technologies.
The hope of those involved with RF ablation is that
the incorporation of CF sensing into RF ablation
catheters will make our dreams come true, including
more permanent PV isolation, greater efﬁcacy, fewer
left atrial ﬂutters due fewer gaps in lines, improved
safety, and quicker procedures. Another important
unanswered question concerns the relative safety
and efﬁcacy of AF ablation with irrigated CF-sensing
RF energy ablation catheters versus the second-
generation cryoballoon. The ongoing Fire and ICE
study in Europe, which is randomizing patients to RF
ablation versus cryoballoon ablation, should shed
light on these questions.
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